A comparison of serum APE1 protein levels of 523 healthy blood donors with APE1 protein levels in biopsies from 172 NSCLC patients and serum of 412 NSCLC patients receiving platinum chemotherapy showed that APE1 is a predictive biomarker for NSCLC prognosis and treatment effect [32]. This evidence concerns the gene APEX1 and non-small cell lung carcinoma.